|
149 T/C
|
|---|
| | |
149 T/C Genotype
|
C allele frequency (%)
|
|---|
|
Study group
|
Total no.
|
CC
|
TC
|
TT
| |
|---|
|
PCaa
|
361
|
4 (1.1)
|
84 (23.3)
|
273 (75.6)
|
12.742
|
|
Stageb
| | | | | |
|
A
|
24
|
1 (4.2)
|
5 (20.8)
|
18 (75.0)
|
14.583
|
|
B
|
184
|
1 (0.5)
|
40 (21.7)
|
143 (77.8)
|
11.413
|
|
C
|
56
|
1 (1.8)
|
16 (28.6)
|
39 (69.6)
|
16.071
|
|
D
|
97
|
1 (1.0)
|
23 (23.7)
|
73 (75.3)
|
12.886
|
|
Organ confined PCa
|
208
|
2 (1.0)
|
45 (21.6)
|
161 (77.4)
|
11.778
|
|
Extraprostatic PCa
|
153
|
2 (1.3)
|
39 (25.5)
|
112 (73.2)
|
14.052
|
|
Localized Pca
|
264
|
3 (1.1)
|
61 (23.1)
|
200 (75.8)
|
12.689
|
|
Metastatic Pca
|
97
|
1 (1.0)
|
23 (23.7)
|
73 (75.3)
|
12.887
|
|
Gradec
| | | | | |
|
Low/Intermediate
|
257
|
1 (0.4)
|
55 (21.4)
|
201 (78.2)
|
11.089
|
|
High
|
104
|
3 (2.9)
|
29 (27.9)
|
72 (69.2)
|
16.826
|
|
Control
|
195
|
3 (1.5)
|
37 (19.0)
|
155 (79.5)
|
11.026
|
|
950 T/C
|
| | |
950 T/C Genotype (%)
|
C allele frequency (%)
|
|
Study group
|
Total no.
|
CC
|
TC
|
TT
| |
|
PCaa
|
361
|
63 (17.4)
|
162 (44.9)
|
136 (37.7)
|
39.889
|
|
Stageb
| | | | | |
|
A
|
24
|
8 (33.3)
|
8 (33.3)
|
8 (33.3)
|
50
|
|
B
|
184
|
36 (19.6)
|
84 (45.6)
|
64 (34.8)
|
42.391
|
|
C
|
56
|
9 (16.0)
|
30 (53.6)
|
17 (30.4)
|
42.857
|
|
D
|
97
|
11 (10.3)
|
39 (41.2)
|
47 (48.5)
|
30.927
|
|
Organ confined PCa
|
208
|
44 (21.2)
|
92 (44.2)
|
72 (34.6)
|
43.269
|
|
Extraprostatic PCa
|
153
|
19 (12.4)
|
70 (45.8)
|
64 (41.8)
|
35.294
|
|
Localized Pca
|
264
|
53 (20.0)
|
122 (46.3)
|
89 (33.7)
|
43.181
|
|
Metastatic Pca
|
97
|
11 (10.4)
|
39 (41.2)
|
47 (48.4)
|
30.927
|
|
Gradec
| | | | | |
|
Low/Intermediate
|
257
|
48 (18.7)
|
116 (45.1)
|
93 (36.2)
|
41.245
|
|
High
|
104
|
15 (14.4)
|
46 (44.3)
|
43 (41.3)
|
36.538
|
|
Control
|
195
|
29 (14.9)
|
98 (50.2)
|
68 (34.9)
|
40
|
-
a Prostate cancer versus control, P = 0.939 and 0.294 by the chi-square test for 149 T/C and 950 T/C, respectively.
-
b According to the Whitmore-Jewett system. Stage A = T1a-bN0M0, Stage B = T1c-2N0M0, Stage C = T3–4N0M0 and Stage D = T1–4N1M0–1 or T1–4N0–1M1. Localized PCa (Stage A + B + C) versus Metastatic PCa (Stage D) P = 0.931 and 0.005 by the chi-square test for 149 T/C and 950T/C, respectively. Organ confined (Stage A + B) versus Extraprostatic PCa (Stage C + D), P = 0.346 and 0.021 by the chi-square test for 149 T/C and 950T/C, respectively.
-
c Low grade = well-differentiated carcinoma (WHO) or Gleason score 2–4 carcinoma, Intermediate grade = moderately differentiated carcinoma (WHO) or Gleason score 5–7 carcinoma, High grade = poorly differentiated carcinoma (WHO) or Gleason score 8–10 carcinoma. C allele frequency, P = 0.884 and 0.520 by the chi-square test for 149 T/C and 950 T/C, respectively.
